Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race

13 October 2026 · By · Wire by Fusion42

Published

13 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 13 October 2026 · Fusion42 review

Roche has signed a $1.2 billion licensing deal with China's Rona Therapeutics to access their RNAi drug candidate targeting ALK7 for obesity treatment, joining other pharma companies in this emerging obesity drug race.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 13 Oct 2026 and 16 Oct 2026.

◆ ◆ The Wire takeaway

You need to act fast on ALK7 if you build obesity therapeutics. Roche's move signals growing validation and funding in RNAi approaches from China, which could leave rivals behind if they hesitate.

◆ Coverage

4 sources · first reported 13 Oct 2026 · latest 16 Oct 2026

◆ Related on Wire

◆ Topics

Biotechobesityalk7rna-interferencelicensing-dealchinabiotech